| Old Articles: <Older 1941-1950 Newer> |
|---|
 |
The Motley Fool
April 19, 2005
Stephen D. Simpson |
Do The Eyes Have It for Bausch & Lomb? New product launches and extensions coupled with improving margins should boost results. Investors, take note.   |
The Motley Fool
April 19, 2005
Stephen D. Simpson |
Does Forest Have the Blues? Hugely dependent on a single drug, Forest is in a precarious position. Though the next couple of years could be a little hairier than what most pharma investors are normally accustomed to, Forest is worth a look. |
The Motley Fool
April 19, 2005
Stephen D. Simpson |
Taking the Air Out of Lincare Lincare has been through Medicare reimbursement cuts before. The big question is: How long before growth resumes? |
BusinessWeek
April 25, 2005
Catherine Arnst |
When Patients Say: Don't Ban My Drug Emotional lobbying can keep a treatment on the market despite serious side effects. |
BusinessWeek
April 25, 2005
Barrett & Carey |
"Off-Label" Drugs: J&J Is Pushing The Envelope Recommending uses for its drugs not intended when approved by the FDA. |
BusinessWeek
April 25, 2005
Catherine Arnst |
Breast Implants: Science vs. Emotion Lobbying and politics are having a huge effect on the debate over whether to allow silicone breast implants back on the market. |
The Motley Fool
April 18, 2005
Stephen D. Simpson |
Is Lilly About to Bloom? Two new diabetes products could add a little punch to this drug-maker's top line. Lilly shares are not really "cheap" these days, but there's a lot to like about a company with no legal overhang, several new drugs, and a decent dividend yield. |
The Motley Fool
April 18, 2005
Rich Smith |
U.S. Government Out for Blood Two companies await as the Institute of Medicine advocates improvements in cord blood banking. Newly public ViaCell has been plummeting along with rival Cryo-Cell, down roughly 40% over the past three months. |
The Motley Fool
April 15, 2005
Brian Gorman |
Relief Pitch for Eli Lilly A ruling upholding the Zyprexa patent is good news for Lilly, but promising drugs in the pipeline are even more encouraging. Investors, take note. |
BusinessWeek
April 25, 2005
Sarah Lacy |
BW50: Gilead's Big Growth Spurt The small biotech rivals the majors in HIV drugs. Now it must expand beyond its niche |
| <Older 1941-1950 Newer> Return to current articles. |
